UNSPSC 51152063: Nelezaprine maleate

This classification denotes a muscle relaxant with the molecular formula C18H21ClN2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Q9L107XJB, chemically known as 3-(9-chloro-5,6-dihydro-11-h-pyrrolo(2,1-b))(3)benzazepine-11-ylidine-n,n-dimethyl-1-propanaminebutenedioate but more generally known as nelezaprine maleate, which bears US NIH Compound Identifier 6436129. Most nations, for tariff and trade purposes, schedule nelezaprine maleate under HS 29339930 and SITC 51577.

As of Q4 2014, NELEZAPRINE MALEATE remains US FDA's Preferred Term for this commodity. Nelezaprine maleate bears US NLM identifiers UMLS ID C2825399 and NCI Concept Code C80980. SMILES: CN(C)CC/C=C\1/C2CCCN2CCC3C1CC(CC3)CL.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51152063 Nelezaprine maleate is a Commodity code that maps poorly to recent state and local procurement activity in the available record. The code names a specific pharmaceutical compound, but the two recent opportunities tagged under it—one soliciting naloxone and drug deactivation systems, the other a Texas HHS exploratory RFI on direct-to-manufacturer prescription programs—do not involve nelezaprine procurement. The naloxone solicitation is a standalone public health supply buy; the Texas RFI is a market-research inquiry about pharmacy benefit program restructuring and does not target any specific drug or product class. State and local governments use this code nominally for pharmaceutical commodities within emergency response and health benefit frameworks, but the recent record shows no actual nelezaprine orders or demand signals.

Issuing-body activity is sparse and geographically scattered. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, with a due date of July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually, to support community health initiatives with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription contracting, a preliminary market-intelligence phase with no award value or formal competitive timeline specified. The code shows no standing repeat buyers, no geographic concentration, and no demonstrated procurement demand for the nominal commodity itself.